ERBB2 and breast carcinoma: Since we showed that trastuzumab induces HER ligand release, resulting in the activation of HER receptors in MDA-MB-453 cells, we hypothesized that a panHER inhibitor such as neratinib could be effective in these cells due to its effectiveness against HER2 positive breast cancer cells [24].